Among other things, the agency explains that DDIs are a critical factor in a drug’s overall benefit-risk profile. The results of in vitro DDI studies and pharmacokinetic (PK) data “provide mechanistic information that can inform the need for and proper design of potential future clinical studies.”
- The evaluation of drug interactions in preclinical stages optimizes novel drug development
- Role of pharmacological efflux receptors in cancer treatment resistance
- Recommended cell-based in vitro testing to assess BCRP protein-mediated transport
- 3rd SCI-RSC Symposium on Transporters in Drug Discovery and Development
- Why evaluate MDR1 receptor affinity in CNS pharmacokinetic assays?